AR070415A1 - Derivados de 3-alquil-piperazina y usos de los mismos - Google Patents

Derivados de 3-alquil-piperazina y usos de los mismos

Info

Publication number
AR070415A1
AR070415A1 ARP090100482A ARP090100482A AR070415A1 AR 070415 A1 AR070415 A1 AR 070415A1 AR P090100482 A ARP090100482 A AR P090100482A AR P090100482 A ARP090100482 A AR P090100482A AR 070415 A1 AR070415 A1 AR 070415A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
cycloalkyl
hydrogen
3alkyl
Prior art date
Application number
ARP090100482A
Other languages
English (en)
Inventor
Robert James Weikert
Ryan Craig Schoenfeld
Matthew C Lucas
David Scott Carter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR070415A1 publication Critical patent/AR070415A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan también composiciones farmacéuticas, métodos de empleo y métodos de obtencion de los compuestos. utiles para depresion y ansiedad. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo, en la que: m es un numero de 1 a 3; n es un numero de 0 a 2; Ar es: indolilo opcionalmente sustituido; indazolilo opcionalmente sustituido; azaindolilo opcionalmente sustituido; azaindazolilo opcionalmente sustituido; 2,3-dihidro-indolilo opcionalmente sustituido; benzotiofenilo opcionalmente sustituido; bencimidazolilo opcionalmente sustituido; benzoxazolilo opcionalmente sustituido; benzotiazolilo opcionalmente sustituido; quinolinilo opcionalmente sustituido; isoquinolinilo opcionalmente sustituido; naftalenilo opcionalmente sustituido; o fenilo opcionalmente sustituido; uno de X, Y y Z es N y los demás son CRa o X, Y y Z son CRa en el que cada Ra es con independencia hidrogeno o R7; R1 es: hidrogeno; alquilo C1-6 o un grupo protector de amina; R2 es: alquilo C3-6; alcoxi C1-6-alquilo C1-3; hidroxi-alquilo C1-6; cicloalquilo C3-6; cicloalquil C3-6-alquilo C1-3; cicloalquiloxi C3-6-alquilo C1-3; cicloalquil C3-6-alcoxi C1-3-alquilo C1-3; arilo; heteroarilo; ariloxi-alquilo C1-3; heteroariloxi-alquilo C1-3; heterociclilo; o heterociclil-alquilo C1-3; R3 es: hidrogeno; o alquilo C1-6; o R2 y R3 junto con el átomo al que están unidos pueden formar un cicloalquilo C3-6; R4 es: hidrogeno; o alquilo C1-6; o R2 y R4 junto con los átomos a los que están unidos pueden formar un anillo heterocíclico de cinco o seis eslabones.
ARP090100482A 2008-02-15 2009-02-12 Derivados de 3-alquil-piperazina y usos de los mismos AR070415A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2897808P 2008-02-15 2008-02-15

Publications (1)

Publication Number Publication Date
AR070415A1 true AR070415A1 (es) 2010-04-07

Family

ID=40521728

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100482A AR070415A1 (es) 2008-02-15 2009-02-12 Derivados de 3-alquil-piperazina y usos de los mismos

Country Status (15)

Country Link
US (1) US7998963B2 (es)
EP (1) EP2254884B1 (es)
JP (1) JP2011512340A (es)
KR (1) KR20100101171A (es)
CN (1) CN101952278A (es)
AR (1) AR070415A1 (es)
AU (1) AU2009214190A1 (es)
BR (1) BRPI0908807A2 (es)
CA (1) CA2713378A1 (es)
CL (1) CL2009000317A1 (es)
IL (1) IL206951A0 (es)
MX (1) MX2010008778A (es)
PE (1) PE20091470A1 (es)
TW (1) TW200938533A (es)
WO (1) WO2009101018A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753528A (zh) * 2009-12-04 2012-10-24 霍夫曼-拉罗奇有限公司 作为单胺重摄取抑制剂的二苯基氮杂*衍生物
CN103508981A (zh) * 2012-06-18 2014-01-15 北京美倍他药物研究有限公司 新的哌嗪衍生物及其医药用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB950872A (en) 1961-03-17 1964-02-26 Soc Ind Fab Antibiotiques Sifa Substituted pyridyl-ethyl-piperazines
JP2003506365A (ja) * 1999-07-29 2003-02-18 イーライ・リリー・アンド・カンパニー ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン：セロトニンアゴニスト
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
ATE260281T1 (de) * 2000-08-03 2004-03-15 Pfizer Prod Inc Diazacyclooctanverbindungen und ihre therapeutische verwendung
CN1331864C (zh) * 2001-03-02 2007-08-15 神经研究公司 新型2,5－二氮杂二环[2.2.1]庚烷衍生物
BR0209932A (pt) 2001-05-22 2004-10-13 Neurogen Corp Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto
CZ20033529A3 (cs) * 2001-06-07 2004-04-14 F. Hoffman-La Roche Ag Nové deriváty indolu s afinitou k receptoru 5-HT6
AU2002309435B2 (en) * 2001-06-11 2008-08-14 Biovitrum Ab (Publ) Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
US7452888B2 (en) * 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
JP2005289816A (ja) * 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
WO2004080407A2 (en) 2003-03-07 2004-09-23 Predix Pharmaceuticals Holdings, Inc. New serotonin modulating compounds and uses therefor
BRPI0414136A (pt) * 2003-09-04 2006-10-31 Aventis Pharma Inc indóis substituìdos como inibidores de poli(adp-ribose) polimerase (parp)
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
RU2377988C2 (ru) * 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Модуляция воспалительных и метастатических процессов
EP1724267B1 (en) * 2004-02-26 2013-11-06 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative
MXPA06014213A (es) * 2004-06-18 2007-03-12 Neurosearch As Novedosos derivados de piperazina sustituidos por alquilo y su uso como inhibidores de la recaptacion del neurotransmisor monoamina.
EP1773653A1 (en) 2004-07-01 2007-04-18 Ringprop Trading Limited Shroud or ring propeller blade interface
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI329641B (en) * 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
WO2007038367A1 (en) * 2005-09-23 2007-04-05 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
WO2007127262A2 (en) * 2006-04-26 2007-11-08 The University Of Montana Enantiomers of 2'-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics
US8530475B2 (en) * 2006-05-18 2013-09-10 Janssen Pharmaceutica Nv Bridged aryl piperazines derivatives useful for the treatment of CNS, GI-urinary and reproductive disorders
EP2061460A2 (en) * 2006-08-07 2009-05-27 Albany Molecular Research, Inc. 2-aminobenzoxazole carboxamides as 5ht3 modulators
EP2061774B1 (en) * 2006-08-17 2010-12-22 F. Hoffmann-La Roche AG Arylpiperazine derivatives and uses thereof
TW200831498A (en) * 2006-10-13 2008-08-01 Otsuka Pharma Co Ltd Heterocyclic compound
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬

Also Published As

Publication number Publication date
EP2254884A2 (en) 2010-12-01
CN101952278A (zh) 2011-01-19
JP2011512340A (ja) 2011-04-21
EP2254884B1 (en) 2013-05-01
MX2010008778A (es) 2010-08-30
AU2009214190A1 (en) 2009-08-20
KR20100101171A (ko) 2010-09-16
IL206951A0 (en) 2010-12-30
CL2009000317A1 (es) 2010-02-26
PE20091470A1 (es) 2009-09-24
BRPI0908807A2 (pt) 2015-07-28
CA2713378A1 (en) 2009-08-20
WO2009101018A2 (en) 2009-08-20
US20090209553A1 (en) 2009-08-20
US7998963B2 (en) 2011-08-16
TW200938533A (en) 2009-09-16
WO2009101018A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
RS54910B1 (sr) Jedinjenje indola i njegova upotreba u farmaciji
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
ECSP109932A (es) Compuestos de biciclolactama sustituida
AR073760A1 (es) Derivados heterociclicos y metodos de uso de los mismos
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
AR076579A1 (es) Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc).
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
RS54708B1 (en) ARYLETINYL DERIVATIVES
AR054797A1 (es) Derivados de quinolina, composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de infecciones virales por virus de la familia flaviviridae, tal como hcv.
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR062405A1 (es) Derivados de isoindol
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR065863A1 (es) Derivados de imidazolidinona
CU20080165A7 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
ECSP10010380A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
RS51462B (en) TRIAZOLOPYRIDINE CARBOXAMID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION

Legal Events

Date Code Title Description
FB Suspension of granting procedure